NCT01498627View on ClinicalTrials.gov

Cervarix Long-term Safety Surveillance

CompletedOBSERVATIONAL

Enrollment

2,945

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix

3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).

OTHER

Data collection

PGRx information system

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01498627 - Cervarix Long-term Safety Surveillance | Biotech Hunter | Biotech Hunter